Leadership team expanded with addition of Chief Corporate Development Officer, Ted Hibben, a 25-year venture-stage business development biotherapeutic industry veteran
Total venture funding tops $50M to date

Amelia™-1 Study is testing if evexomostat can improve patients' safety and clinical response to a PI3K inhibitor plus an estrogen receptor degrader. Evexomostat, a novel MetAP2 inhibitor, controlled PI3K-induced hyperglycemia in the first study patient, consistent with pre-clinical data. Further, ctDNA data shows no evidence of residual PIK3CA mutation in blood after 6 weeks of treatment.

New Module Automates Regulatory Updates During Corporate Transitions

Lead cancer drug candidate, ST-001 nanoFenretinide, has received Institutional Review Board ("IRB") approval for its upcoming clinical trials for T-Cell Lymphomas.

Powerful New Solutions Help Therapeutic Developers Reduce Time-to-Clinic While Increasing Yield and Safety

Pharmacy benefit manager's new brand pillars leverage strengths to better serve their partners and clients.

Ongoing rise in customers ordering Rx medication from Pharmacies like Canada Pharmacy

Coronary Heart Disease (CHD) prevention nearly twice as effective when using CARDIO inCode
as method to target treatment

Brainify.AI, an innovative company leveraging artificial intelligence to revolutionize the treatment of depression, is excited to announce it has joined Johnson & Johnson Innovation JLABS (JLABS) as a resident company. This marks a significant milestone for Brainify.AI and is another indication of the value and promise the company brings to the medical AI field.

A leap into simplifying Super-Resolution Microscopy

A University of Chicago team identified a special type of stem cell that heals damaged bowel tissue in mice, a discovery that may have direct application to humans with inflammatory bowel disease. These early findings, made possible with seed funding from the GI Research Foundation, resulted in a recent five-year, $2.5 million grant from the National Institutes of Health to study those cells in humans.

CMX-2043, a novel, proprietary cytoprotective drug candidate, demonstrated excellent safety and tolerability in a Phase 1 single ascending and multiple ascending dose (SAD-MAD) clinical trial. CMX-2043 has previously demonstrated safety and efficacy in extensive preclinical pharmacology, toxicology and TBI translational studies. CMX-2043 will be Phase 2-ready by the first quarter of 2024.

PA-based clinical technology provider assisTek has announced new features to its upcoming software release, including AI Integration, a Proprietary OS, SSO & Remote Provisioning, to add to its growing suite of eCOA & ePRO solutions.

In-depth Analysis and Testing Unveil the Leading Brain-Boosting Supplements

A Leap Forward for Patients, a Promising Opportunity for Investors, and a Revolutionary Tool for Physicians

Just in Time GCP named among Best Workplaces by Inc. Magazine

Updates to Tempo's Manufacturing Execution System and Connected Manufacturing Network Drive Greater Efficiency and Scalability

Data Science Meets Life Science: AI Challenges & Opportunities in Biopharma, Synthetic Biology and Beyond

LCTG-001 on course to be the first FDA-approved biologic from human milk

In a clinical validation study published on Scientific Reports, UNITY RhD NIPT and Fetal antigen NIPT demonstrated 100% sensitivity, 100% specificity, 99.9% precision with 0.1% no-call rate across 3,921 NIPT assays.

Tampa-based site expands study capabilities and patient comfort

Funding Accelerates the Development of Compliance Automation Solutions